EGFR knockdown suppressed LSCC cell growth, infiltration and migration, and EGFR inhibitors were proved to have anti-laryngeal cancer effects in vitro and in vivo (Ren, Wang & Qi, 2021; Yang et al., 2020). The gene discussed is EGFR; the disease is laryngeal carcinoma.